American Heart Journal
Volume 141, Issue 2, Supplement , Pages S26-S35 , February 2001

Coronary stenting and platelet glycoprotein IIb/IIIa receptor blockade in acute myocardial infarction

References 

  1. GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary artery patency, ventricular function and survival after acute myocardial infarction. N Engl J Med. 1993;329:1615–1622
  2. The GUSTO Investigators . An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993;329:673–682
  3. Zijlstra F, de Boer JM, Hoorntje JCA, et al.  A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction. N Engl J Med. 1993;328:680–684
  4. Grines CL, Browne KF, Marco JA, et al.  comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. N Engl J Med. 1993;328:673–679
  5. Gibbons RJ, Holmes DR, Reeder GS, et al.  Immediate angioplasty compared with the administration of a thrombolytic agent followed by conservative treatment for myocardial infarction. N Engl J Med. 1993;328:685–691
  6. Weaver WD, Simes J, Betriu A, et al.  Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction. A quantitative review. JAMA. 1997;278:2093–2098
  7. The GUSTO IIb Angioplasty Substudy Investigators . A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. N Engl J Med. 1997;336:1621–1628
  8. Stone GW, Grines CL, Browne BR, et al.  Implications of recurrent ischemia after reperfusion therapy in acute myocardial infarction: a comparison of thrombolytic therapy and primary coronary angioplasty. J Am Coll Cardiol. 1995;26:66–72
  9. Nakagawa Y, Iwasaki Y, Kimura T, et al.  Serial angiographic follow-up after successful direct angioplasty for acute myocardial infarction. Am J Cardiol. 1996;78:980–984
  10. Brodie BR, Grines CL, Ivanhoe R, et al.  Six-month clinical and angiographic follow-up after direct angioplasty for acute myocardial infarction. Circulation. 1994;25:156–162
  11. Garcia-Cantu E, Spaulding C, Corcos T, et al.  Stent implantation in acute myocardial infarction. Am J Cardiol. 1996;77:451–454
  12. Rodriguez AE, Fernandez M, Santaera O, et al.  Coronary stenting in patients undergoing percutaneous transluminal coronary angioplasty during acute myocardial infarction. Am J Cardiol. 1996;77:685–689
  13. Le May MR, Labinaz M, Beanlands RSB, et al.  Usefulness of intracoronary stenting in acute myocardial infarction. Am J Cardiol. 1996;78:148–152
  14. Antoniucci D, Valenti R, Buonamici P, et al.  Direct angioplasty and stenting of the infarct-related artery in acute myocardial infarction. Am J Cardiol. 1996;78:568–571
  15. Mehta RH, Bates ER. Coronary stent implantation in acute myocardial infarction. Am Heart J. 1999;137:603–611
  16. Nishida Y, Nonoaka H, Ueda K, et al.  In-hospital outcome of primary stenting for acute myocardial infarction using Wiktor coil stent: results from a multicenter randomized PRISAM study [abstract]. Circulation. 1997;96(suppl I):I-397
  17. Inoue N, Tamai H, Nishida Y, et al.  Economic assessment in the Primary Stenting for Acute Myocardial Infarction (PRISAM) study [abstract]. Circulation. 1997;96(suppl I):I-530
  18. Ueda K, Nishida Y, Iwase T, et al.  Quantitative angiographic restenosis of primary stenting using Wiktor coil stent for acute myocardial infarction: results from a multicenter randomized PRISAM study [abstract]. Circulation. 1997;96(suppl I):I-531
  19. Saito S, Hosokawa G. Primary Palmaz-Schatz stent implantation for acute myocardial infarction: the final results of Japanese PASTA (Primary Angioplasty versus Stent Implantation in Acute Myocardial Infarction in Japan) trial [abstract]. Circulation. 1997;96(suppl I):I-595
  20. Antoniucci D, Santoro GM, Bolognese L, et al.  A clinical trial comparing primary stenting of infarct-related artery with optimal primary angioplasty for acute myocardial infarction: results from the Florence Randomized Elective Stenting in Acute Coronary Occlusions (FRESCO) trial. J Am Coll Cardiol. 1998;31:1234–1239
  21. Suryapranata H, van’t Hof AWJ, Hoorntje JCA. Randomized comparison of coronary stenting with balloon angioplasty in selected patients with acute myocardial infarction. Circulation. 1998;97:2502–2505
  22. Rodriguez A, Bernardi V, Fernandez M, et al.  In-hospital and late results of coronary stents versus conventional balloon angioplasty in acute myocardial infarction (GRAMI trial). Am J Cardiol. 1998;81:1286–1291
  23. Stone GW, Morice MC, Cox D, et al.  Predictors of six-month event-free survival after mechanical reperfusion in acute myocardial infarction. The PAMI Stent randomized trial [abstract]. J Am Coll Cardiol. 1999;33(suppl A):379A
  24. Stone GW, Morice M-C, Lansky A, et al.  Routine stent implantation reduces restenosis after primary angioplasty in acute myocardial infarction. Results from the PAMI Stent randomized trial [abstract]. J Am Coll Cardiol. 1999;33(suppl A):361A
  25. Stone GW, Brodie BR, Griffin JJ, et al.  Clinical and angiographic follow-up after primary stenting in acute myocardial infarction. The Primary Angioplasty in Myocardial Infarction (PAMI) Stent Pilot Trial. Circulation. 1999;99:1548–1554
  26. Stone GW, Garcia E, Griffin J, et al.  Does stent implantation in acute myocardial infarction degrade TIMI flow and result in higher early mortality than PTCA? The PAMI Stent randomized trial [abstract]. Circulation. 1998;98(suppl I):I-151
  27. Antoniucci D, Valenti R, Santoro GM, et al.  Primary coronary infarct artery stenting in acute myocardial infarction. Am J Cardiol. 1999;84:505–510
  28. Webb JG, Carere RG, Hilton JD, et al.  Usefulness of coronary stenting in cardiogenic shock. Am J Cardiol. 1997;79:81–84
  29. Nakagawa Y, Hamasaki N, Kimura T, et al.  Stent implantation in acute myocardial infarction is more beneficial in patients with cardiogenic shock than those without [abstract]. J Am Coll Cardiol. 1998;31(suppl A):232A
  30. Suarez de Lezo J, Medina A, Pan M, et al.  Intracoronary stent treatment in the early phase of cardiogenic shock [abstract]. Eur Heart J. 1998;19(suppl):29
  31. Fabbiocchi F, Montorsi P, Loaldi A, et al.  Acute and long-term results of elective coronary stent implantation in cardiogenic shock [abstract]. Eur Heart J. 1998;19(suppl):29
  32. Antoniucci D, Valenti R, Santoro GM, et al.  Systematic direct angioplasty and stent-supported direct angioplasty therapy for cardiogenic shock complicating acute myocardial infarction: in-hospital and long-term survival. J Am Coll Cardiol. 1998;31:294–300
  33. Fuster V, Badimon L, Badimon JJ, et al.  The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med. 1992;326:242–250
  34. Topol EJ. Toward a new frontier in myocardial reperfusion therapy. Emerging platelet preeminence. Circulation. 1998;97:211–218
  35. Becker RC. Thrombosis and the role of the platelet. Am J Cardiol. 1999;83(suppl 9A):3E–6E
  36. ISIS-2 (Second International Study Group of Infarct Survival) Collaborative Group . Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction. Lancet. 1988;2:349–360
  37. Pope CF, Ezekowitz MD, Smith EO, et al.  Detection of platelet deposition at the site of peripheral balloon angioplasty using Indium-111 platelet scintigraphy. Am J Cardiol. 1985;55:495–497
  38. Gasperetti CM, Gonias SL, Gimple LW, et al.  Platelet activation during coronary angioplasty in humans. Circulation. 1993;88:2728–2734
  39. Wilentz JR, Sanborn TA, Haudenschild CC, et al.  Platelet accumulation in experimental angioplasty: time course in relation to cardiovascular injury. Circulation. 1987;75:636–642
  40. Gawaz M, Neumann FJ, Ott I, et al.  Platelet function in acute myocardial infarction treated with primary angioplasty. Circulation. 1996;93:229–237
  41. Iwabuchi M, Haruta S, Taguchi A, et al.  Intravascular ultrasound findings after successful primary angioplasty for acute myocardial infarction: predictors of abrupt occlusion. J Am Coll Cardiol. 1997;30:1437–1444
  42. Lincoff AM, Korngold S. An overview of platelet GP IIb/IIIa receptor antagonists trials. Eur Heart J. 1999;1(suppl E):E18–E26
  43. Chronos N, Marciniak SJ, Nakada MT. Binding specificity and associated effects of platelet GP IIb/IIIa inhibitors. Eur Heart J. 1999;1(suppl E):E11–E17
  44. Lefkovits J, Ivanhoe RJ, Califf RM, et al.  Effects of platelet glycoprotein IIb/IIa receptor blockade by a chimeric monoclonal antibody (abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction. Am J Cardiol. 1996;77:1045–1051
  45. The RESTORE Investigators . Effect of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation. 1997;96:1445–1453
  46. Brener SJ, Barr LA, Burchenal JEB, et al.  Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. Circulation. 1998;98:734–741
  47. The EPILOG Investigators . Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med. 1997;336:1689–1696
  48. The CAPTURE Investigators . Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE Study. Lancet. 1997;349:1429–1435
  49. Aggarwal RK, Ireland DC, Azrin MA, et al.  Antithrombotic potential of polymer-coated stents eluting platelet glycoprotein IIb/IIIa receptor antibody. Circulation. 1996;94:3311–3317
  50. Makkar RR, Litvack F, Eigler NL, et al.  Effects of GP IIb/IIIa receptor monoclonal antibody (7E3), heparin, and aspirin in an ex vivo canine arteriovenous shunt model of stent thrombosis. Circulation. 1997;95:1015–1021
  51. Neumann FJ, Gawaz M, Ott I, et al.  Prospective evaluation of hemostatic predictors of subacute stent thrombosis after coronary Palmaz-Schatz stenting. J Am Coll Cardiol. 1996;27:15–21
  52. Leon MB, Baim DS, Popma JJ, et al.  A clinical trial comparing three antithrombotic drug regimens after coronary artery stenting. N Engl J Med. 1998;339:1665–1671
  53. Schomig A, Neumann FJ, Kastrati A, et al.  A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med. 1996;334:1084–1089
  54. The EPISTENT Investigators . Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet. 1998;352:87–92
  55. Neumann FJ, Kastrati A, Dirschinger J, et al.  Use of platelet glycoprotein IIb/IIIa blockade in acute myocardial infarction treated with intracoronary stenting: 30-day clinical results of a randomized study ([abstract]. J Am Coll Cardiol. 1999;33(suppl A):338A
  56. Montalescot G. Abciximab before Direct angioplasty and stenting in Myocardial Infarction Regarding Acute and Long-term follow-up (ADMIRAL). Presented at the 48th Scientific Session of the American College of Cardiology. New Orleans. March 1999;
  57. Stone GW. Stenting and IIb/IIIa receptor blockade in acute myocardial infarction: an introduction to the CADILLAC trial. J Invas Cardiol. 1998;10(suppl B):36B–47B
  58. Neumann FJ, Blasini R, Schmitt C, et al.  Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction. Circulation. 1998;98:2695–2701
  59. Coller BS. GP IIb/IIIa antagonists: pathophysiologic and therapeutic insights from studies of c7E3 Fab. Thromb Haemost. 1997;78:730–755
  60. Cox AD, Devine DV. Factor XIIIa binding to activated platelet is mediated through activation of glycoprotein IIb/IIIa. Blood. 1994;83:1006–1016
  61. Coller BS. Augmentation of thrombolysis with antiplatelet drugs: an overview. Coron Artery Dis. 1996;6:911–914
  62. Van den Merkhof LFM, Zijlstra F, Olsson H, et al.  Abciximab in the treatment of acute myocardial infarction eligible for primary percutaneous transluminal coronary angioplasty. Results of the Glycoprotein Receptor Antagonist Patency Evaluation (GRAPE) Pilot Study. J Am Coll Cardiol. 1999;33:1528–1532
  63. Ohman EM. Results of the SPEED (Strategies for Patency Enhancement in the Emergency Department) study. Presented at the 47th Scientific Session of the American College of Cardiology. Atlanta. March 1998;
  64. Antman EM, Giugliano RP, Gibson CM, et al.  Abciximab facilitates the rate and extent of thrombolysis. Results of the Thrombolysis in Myocardial Infarction (TIMI) 14 trial. Circulation. 1999;99:2720–2732

☆ Reprint requests: Giovanni M. Santoro, MD, Cardiology I, Careggi Hospital, Viale Morgagni 85, 50134 Firenze, Italy. E-mail: cardiologia1@ao-careggi.toscana.it

PII: S0002-8703(01)70041-5

American Heart Journal
Volume 141, Issue 2, Supplement , Pages S26-S35 , February 2001

Article Tools

* Image Usage & Resolution